Anti-inflammatory effects of 4,4'-diaminodiphenyl sulfone (dapsone) in lipopolysaccharide-treated spleen cells: selective inhibition of inflammation-related cytokines

지질다당류를 투여한 비장세포에서 4,4'-diaminodiphenyl sulfone (dapsone)의 항염증 효과: 염증 관련 사이토카인의 선택적 억제

  • Moon, Sun-Young (Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University) ;
  • Joo, Hong-Gu (Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University)
  • 문선영 (제주대학교 수의과대학 수의약리학실) ;
  • 주홍구 (제주대학교 수의과대학 수의약리학실)
  • Received : 2015.06.10
  • Accepted : 2015.07.28
  • Published : 2015.09.30


4,4'-diaminodiphenyl sulfone (dapsone) is a sulfone drug that has antibacterial effects on a variety of bacteria, especially Mycobacterium leprae; thus, it has been used to treat leprosy. Previous studies demonstrated that dapsone inhibits integrin-mediated adherence of neutrophils and production of prostaglandin $E_2$ by polymorphonuclear leukocytes. Hence, dapsone may act in immune cells and regulate cell-mediated inflammation processes. However, its anti-inflammatory effects remain unclear. The present study demonstrated that dapsone modulates the production of inflammation-related cytokines in immune cells. We employed the spleen cells of mice, which are major immune cells, and lipopolysaccharide (LPS) as a causative agent of inflammation for experiments. Dapsone induced a proportional change in splenocyte subsets and the apoptosis of spleen cells. Interestingly, dapsone decreased the production of tumor necrosis factor-alpha and interleukin (IL)-10, but not IL-6, in LPS-treated spleen cells. In other assays, we measured the dapsone-induced production of nitric oxide (NO) and the expression of activation markers of spleen cells. Dapsone decreased NO production in LPS-treated spleen cells. Taken together, our results demonstrate that dapsone has anti-inflammatory effects in immune cells and provide new insight into the potential uses of this agent.


Supported by : 제주대학교


  1. Anderson R. Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes in vitro. Antimicrob Agents Chemother 1985, 27, 257-262.
  2. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992, 98, 135-140.
  3. Chakravortty D, Hensel M. Inducible nitric oxide synthase and control of intracellular bacterial pathogens. Microbes Infect 2003, 5, 621-627.
  4. Coleman MD. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology 2001, 162, 53-60.
  5. Croft M, Duan W, Choi H, Eun SY, Madireddi S, Mehta A. TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol 2012, 33, 144-152.
  6. Joo HG, Goedegebuure PS, Sadanaga N, Nagoshi M, von Bernstorff W, Eberlein TJ. Expression and function of galectin-3, a ${\beta}$-galactoside-binding protein in activated T lymphocytes. J Leukoc Biol 2001, 69, 555-564.
  7. Kim MH, Byon YY, Ko EJ, Song JY, Yun YS, Shin T, Joo HG. Immunomodulatory activity of ginsan, a polysaccharide of Panax ginseng, on dendritic cells. Korean J Physiol Pharmacol 2009, 13, 169-173.
  8. Kountouras J, Zavos C, Chatzopoulos D. Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med 2004, 8, 317-328.
  9. Marzio R, Mauël J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol 1999, 21, 565-582.
  10. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000, 117, 1162-1172.
  11. Plotnikova N, Miller JL. Dermatitis herpetiformis. Skin Therapy Lett 2013, 18, 1-3.
  12. Ramos-e-Silva M, Rebello PFB. Leprosy. Recognition and treatment. Am J Clin Dermatol 2001, 2, 203-211.
  13. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012, 33, 571-577.
  14. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J. Biology of interleukin-10. Cytokine Growth Factor Rev 2010, 21, 331-344.
  15. Shipkova M, Wieland E. Surface markers of lymphocyte activation and markers of cell proliferation. Clin Chim Acta 2012, 413, 1338-1349.
  16. Van Zyl JM, Basson K, Kriegler A, van der Walt BJ. Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system: a possible correlation with their anti-inflammatory properties. Biochem Pharmacol 1991, 42, 599-608.
  17. Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res 2014, 306, 103-124.

Cited by

  1. Fermented antler extract enhances the viability and interleukin-12 production of spleen cells vol.56, pp.3, 2016,